This report provides guidance for countries to enhance the functioning and transparency of the patent system for the timely and affordable access to lifesaving treatment. Affordable access to treatment is closely linked with the aspiration to ensure health and well-being for all, as embodied in the Sustainable Development Goal (SDG).

What are we to do about antibiotic resistance? Last week, another government report repeated stark warnings about the crisis, and offered some suggestions to improve the situation. The UK report, prepared by a panel chaired by the economist Jim O'Neill, naturally focused on financial incentives, including US$1-billion prizes for pharmaceutical firms that develop new antimicrobial drugs.

Original Source

The Union Cabinet approved the National Intellectual Property Rights (IPR) Policy that will lay the future roadmap for intellectual property in India. The Policy recognises the abundance of creative and innovative energies that flow in India, and the need to tap into and channelise these energies towards a better and brighter future for all.

The spread of pests and pathogens that damage plant life could cost global agriculture $540 billion a year, according to this report released by the Royal Botanic Gardens in London. An increase in international trade and travel had left flora facing rising threats from invasive pests and pathogens, and called for greater biosecurity measures.

Indian scientists must develop domestic genetically modified crops rather than rely on unsuitable foreign technology.

Original Source

The outrageous price rise of the 62-year-old drug, Daraprim (Pyrimethamine) has sent the United States medical fraternity into a dizzy. The price of the drug was raised from USD 13.50 to USD 750 per pill in just over a month. This obnoxious price rise of over 5,000% came after the New York-based pharmaceutical company Turing Pharmaceuticals acquired the patent for the drug from Impax Laboratories. (Editorial)

Original Source

Judgement of the Delhi High Court in the matter of Merck Sharp & Dohme Corporation & Others Vs Glenmark Pharmaceuticals Ltd. dated 07/10/2015 regarding infringement of Merck Sharp's patented anti diabetic drugs sold under the brand name JANUVIA and JANUMET.

Order of the Delhi High Court in the matter of Bayer Corporation Vs Union of India & Others dated 12/08/2015 regarding patent for a pharmaceutical product titled “Carboxyarly Substituted Diphenyl Ureas”.

Even as India-US trade (in both goods and services) has progressed towards the $100 billion mark, 2013-14 witnessed the emergence of a number of issues which adversely impacted the climate for bilateral trade and investment. Of these, none has been more contentious than the question of India’s IPR regime for pharmaceutical products.

The research and development costs of 68 randomly selected new drugs were obtained from a survey of 10 pharmaceutical firms. These data were used to estimate the average pre-tax cost of new drug development. The costs of compounds abandoned during testing were linked to the costs of compounds that obtained marketing approval. The estimated average out-of-pocket cost per new drug is US$ 403 million (2000 dollars). Capitalizing out-of-pocket costs to the point of marketing approval at a real discount rate of 11% yields a total pre-approval cost estimate of US$ 802 million (2000 dollars).

Pages